posttraumatic neuropathic pain after peripheral nerve leasion
Conditions
Interventions
Group 1: 100 Units Botulinumtoxin-A per nerve und 2 ml Ropivacain 0,5% as perineural injection
Group 2: 1 ml Ropivacain 0,5% and 1 ml NaCl 0,9% (placebo) per nerve
as perineural injection
Sponsors
Abteilung für SchmerzmedizinBerufsgenossenschaftliches Universitätklinikum Bergmannsheil gGmbH Bochum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of painful neuralgia after peripheral nerve injury, average pain > 4 on numeric rating scale (0-10) in the last two weeks, evidence for nerve leasion (current/anamnestic)
Exclusion criteria
Exclusion criteria: Age > 18 years, pregnancy, contraindications against injection or FMRI, other neurological or psychiatric diseases, CRPS (Complex regional pain syndrome)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients with relevant pain reduction (50%) within one week after injection of Botulinumtoxin-A in comparison to placebo with pain diaries, pain questionnaires, quantitative sensory testing, fMRI, conditioned pain modulation | — |
Secondary
| Measure | Time frame |
|---|---|
| Extent of the avergae pain reduction, changes in peripheral sensory system, central pain modulation with pain diaries, pain questionnaires, quantitative sensory testing, fMRI, conditioned pain modulation | — |
Countries
Germany
Contacts
Public ContactNina Kumowski
Abteilung für SchmerzmedizinBerufsgenossenschaftliches Universitätklinikum Bergmannsheil gGmbH Bochum
Outcome results
None listed